- Home
- ANAB vs NB Comparison
ANAB vs NB Comparison
Compare ANAB & NB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- NB
- Stock Information
- Founded
- ANAB 2005
- NB 1987
- Country
- ANAB United States
- NB United States
- Employees
- ANAB N/A
- NB N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- NB Metal Mining
- Sector
- ANAB Health Care
- NB Basic Materials
- Exchange
- ANAB Nasdaq
- NB Nasdaq
- Market Cap
- ANAB 1.0B
- NB 930.8M
- IPO Year
- ANAB 2017
- NB N/A
- Fundamental
- Price
- ANAB $38.47
- NB $5.90
- Analyst Decision
- ANAB Buy
- NB Strong Buy
- Analyst Count
- ANAB 12
- NB 4
- Target Price
- ANAB $63.30
- NB $5.75
- AVG Volume (30 Days)
- ANAB 364.4K
- NB 13.5M
- Earning Date
- ANAB 11-04-2025
- NB 11-06-2025
- Dividend Yield
- ANAB N/A
- NB N/A
- EPS Growth
- ANAB N/A
- NB N/A
- EPS
- ANAB N/A
- NB N/A
- Revenue
- ANAB $169,467,000.00
- NB N/A
- Revenue This Year
- ANAB $37.52
- NB N/A
- Revenue Next Year
- ANAB N/A
- NB N/A
- P/E Ratio
- ANAB N/A
- NB N/A
- Revenue Growth
- ANAB 196.42
- NB N/A
- 52 Week Low
- ANAB $12.21
- NB $1.30
- 52 Week High
- ANAB $40.96
- NB $12.58
- Technical
- Relative Strength Index (RSI)
- ANAB 72.78
- NB 38.47
- Support Level
- ANAB $34.22
- NB $6.89
- Resistance Level
- ANAB $37.08
- NB $8.16
- Average True Range (ATR)
- ANAB 2.03
- NB 0.85
- MACD
- ANAB -0.18
- NB -0.40
- Stochastic Oscillator
- ANAB 68.07
- NB 3.81
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About NB NioCorp Developments Ltd.
NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.